• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

GADD45A May Prevent Inflammation, Fibrosis, and Preserve Cardiac Function

by MM360 Staff | May 26, 2025 | Myeloma News

Source: Pharmacy Times articles The authors are optimistic that GADD45A serves as a foundation for therapeutic approaches to slow the progression of heart failure. Read More

Navigating the Fellowship Journey: A Road Map to Success

by MM360 Staff | May 26, 2025 | Myeloma News

Source: Pharmacy Times articles The process teaches resilience, adaptability, and self-awareness. Read More

The Role of Executive Orders

by MM360 Staff | May 26, 2025 | Myeloma News

Source: Pharmacy Times articles These directives are typically used to shape federal agencies and manage employees in the executive branch. Read More

Attrition rates and treatment outcomes in multiple myeloma: real-world data over a 40-year period

by MM360 Staff | May 26, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Peripheral Blood Flow Cytometry-based Definition of Plasma Cell Leukemia

by MM360 Staff | May 26, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Going Beyond the Allergy Label to Optimize Antibiotic Use Across Care Settings

by MM360 Staff | May 26, 2025 | Myeloma News

Source: Pharmacy Times articles Pharmacists improve outcomes by clarifying and delabeling inaccurate antibiotic allergies. Read More
« Older Entries
Next Entries »

Recent Content

  • Prognostic and clinicopathological value of prognostic nutritional index in patients with multiple myeloma: a meta-analysis
  • Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: AURIGA subgroup analyses
  • Randomized Phase 3 study of pomalidomide cyclophosphamide dexamethasone versus pomalidomide dexamethasone in relapse or refractory myeloma: an Asian Myeloma Network study (AMN003)
  • (no title)
  • The risk of second primary malignancies in patients receiving T-cell directed therapies for multiple myeloma: a systematic review
  • (no title)
  • Impact of residual clonal plasma cells in S-phase at the time of autologous stem cell transplantation on clinical outcomes
  • (no title)
  • Efficacy and toxicity of treatment of smoldering multiple myeloma: a systematic review and meta-analysis
  • (no title)
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT